A US Food and Drug Administration (FDA) investigation of injection-site necrosis in some people who received the 23-valent pneumococcal vaccine has concluded that the benefits of the vaccine outweigh ...

Please provide your email address to receive an email when new articles are posted on . There were less than 0.2 cases of injection site necrosis per million 23-valent pneumococcal vaccine doses.

In a time of confusion and inconsistent information, healthcare professionals want you to know that it’s not too late to get ...

Please provide your email address to receive an email when new articles are posted on . Although vaccines have reduced the burden of pneumococcal disease, pneumonia due to Streptococcus pneumoniae and ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory ...

The FDA approved a 21-valent pneumococcal conjugate vaccine (Capvaxive) for preventing invasive pneumococcal disease and pneumococcal pneumonia in adults, Merck announced on Monday. Specifically ...